{"contentid": 488579, "importid": NaN, "name": "Galapagos refocuses pipeline", "introduction": "Belgium-based biotech Galapagos has announced operational highlights and plans for refocussing of its clinical pipeline, along with its first-quarter 2021 financial results.", "content": "<p>Belgium-based biotech Galapagos (Euronext: GLPG) has announced operational highlights and plans for refocussing of its clinical pipeline, along with its first-quarter 2021 financial results.</p>\n<p>Onno van de Stolpe, chief executive of Galapagos, commented: &ldquo;These last months, we completed a review of our portfolio and development plans with the goal to select a more risk-balanced pipeline. We decided to retain our focus on novel targets to address unmet medical needs in inflammation, fibrosis, and kidney diseases. We also remain fully committed to the launch of Jyseleca in Europe. Moving forward with confidence, we decided to:</p>\n<ul>\n<li>Refocus our clinical pipeline by critically examining its risk profile and breadth;</li>\n<li>Cut significant cost in the organization to support this re-sized pipeline development;</li>\n<li>Task our business development team to identify and execute on a transformative opportunity.</li>\n</ul>\n<p>&ldquo;We believe that our strong cash position, expert teams, and solid scientific foundation position us well for future growth,&rdquo; he said.</p>\n<h2><strong>Refocused pipeline</strong></h2>\n<p>In the revision exercise, Galapagos set goals to focus and adjust the overall risk profile of its clinical pipeline. Consequently, it has prioritized those assets with what it believes have enhanced chances of clinical success core therapeutic areas. These are:</p>\n<ul>\n<li>Galapagos is testing its lead Toledo program &lsquo;3970, a SIK2/3 inhibitor, in five proof-of -concept studies in different indications, and pending the outcome of the studies, it plans to roll out our further development plans in the second half of the year;</li>\n<li>It has selected an additional molecule from its Toledo program, SIK2/3 inhibitor '4876, as a candidate to accelerate from pre-clinical phase into clinical development;</li>\n<li>It aims to progress TYK2 inhibitor &lsquo;3667 into Phase IIb;</li>\n<li>It has selected chitinase inhibitor &rsquo;4617 to progress to Phase II in IPF and decided to stop development of other IPF molecule &rsquo;1205;</li>\n<li>It has stopped further work on &lsquo;4059 for metabolic disease, given that this is not a core therapeutic area;</li>\n<li>It has discontinued early research efforts in metabolic diseases and osteoarthritis; and</li>\n<li>Has challenged and fine-tuned its stage-gating process to advance compounds.</li>\n</ul>\n<h2><strong>Revenues and other income&nbsp;from continuing operations</strong></h2>\n<p>Galapagos revenues and other income from continuing operations for the first three months of 2021 increased to 124.2 million euros ($151 million) compared to 103.6 million euros in the first three months of 2020. Revenues from the Gilead collaboration in the first three months of 2021 (113.7 million euros) related to (i) the exclusive access to its drug discovery platform (57.8 million euros), (ii) the filgotinib revenue recognition (55.3 million euros) and (iii) royalties (0.7 million euros).</p>\n<p>Galapagos realized a net loss from continuing operations of 12.8 million euros for the first three months of 2021, compared to a net loss of 52.3 million euros for the first three months of 2020.</p>\n<p>The company reported an operating loss amounting to 50.8 million euros for the first three months of 2021, compared to an operating loss of 46.2 million euros for the same period last year.</p>", "date": "2021-05-10 11:18:00", "meta_title": "Galapagos refocuses pipeline", "meta_keywords": "Galapagos, Refocussing, Pipeline, Financials", "meta_description": "Galapagos refocuses pipeline", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-10 09:57:28", "updated": "2021-05-10 11:18:05", "access": NaN, "url": "https://www.thepharmaletter.com/article/galapagos-refocuses-pipeline", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "galapagos_large.jpg", "image2id": "galapagos_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Inflammatory diseases, Nephrology and Hepatology", "topic_tag": "Financial, Management, Research", "geography_tag": "Belgium", "company_tag": "Galapagos", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-10 11:18:00"}